MedTrace Logo

PF-06372865 in Subjects With Photosensitive Epilepsy

NCT02564029 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-03-14

Study results available
· View outcomes & findings →

Summary

PF-06372865 in subjects with photosensitive epilepsy

Conditions

  • Reflex Epilepsy, Photosensitive

Interventions

DRUG

PF-06372865

Single dose

DRUG

Placebo

Placebo for PF-06372865 and placebo for lorazepam

DRUG

Lorazepam

2 mg single oral dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-16
Primary Completion
2017-01-10
Completion
2017-02-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02564029 on ClinicalTrials.gov